Grapefruit-midazolam interaction varies with juice characteristics
(HealthDay)—The interaction between grapefruit juice and midazolam varies based on grapefruit juice-related characteristics such as the amount of furanocoumarin, according to a study published online Aug. 9 in the Journal of Clinical Pharmacology.
Marina Kawaguchi-Suzuki, Pharm.D., Ph.D., from the University of Florida in Gainesville, and colleagues conducted a trial involving 12 healthy volunteers to examine the effect of regular grapefruit juice (RGJ) and a novel, low furanocoumarin hybrid grapefruit juice (HGJ) on the metabolism of oral midazolam, compared with water as a control.
The researchers found that the point estimate for the RGJ/water midazolam area under the curve (AUC) geometric mean ratio was 1.22 percent. The point estimate for the HGJ/water midazolam AUC ratio was within the bioequivalence range of 80 to 125 percent, indicating no interaction. In a systematic review of the evidence of the pharmacokinetic alteration of midazolam by grapefruit juice, most studies showed alteration in midazolam pharmacokinetics, supporting CYP3A activity inhibition as a likely mechanism; however, there was wide variation in the cohorts included and extent of pharmacokinetic interaction.
"The current study indicated grapefruit juice-drug interaction varies substantially based on patient characteristics and/or grapefruit juice product-related factors, including the amount of furanocoumarin constituents present in the juice," the authors write.
One author was an inventor on patent applications for hybrid grapefruit 914.
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.